Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 9 of 9 results for goserelin

  1. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

    Technology appraisal guidance
    Published
    14 August 2024
    View recommendations

    Sections for TA995

  2. Further research is recommended to resolve uncertainties about the clinical effectiveness of degarelix compared with luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced hormone-dependent prostate cancer, particularly in subgroups of people with preexisting cardiovascular disease, people with skeletal (including spinal) metastases and people with impending ureteric and urethral obstruction. Research should be planned as part of well-conducted randomised clinical trials.

    luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced...

    Research recommendation
    Published
    17 October 2016

  3. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA404

  4. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development Reference number: GID-TA10261 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Prostate cancer (QS91)

    This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    30 December 2021
    View quality statements

    Sections for QS91

  6. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA832

  7. Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

    Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.

    Technology appraisal guidance
    Published
    14 August 2024
    View recommendations

    Sections for TA996

  8. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued Reference number: GID-TA10377

    Technology appraisal guidance
    Discontinued

  9. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

    Technology appraisal guidance
    Published
    16 April 2025

    Sections for TA1057